Disc Medicine, Inc. (IRON): Shareholders' Equity
$739.83M
As of 2025-12-31
$644.16M
As of 2026-06-30
+61.2%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $739.83M | +66.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $443.59M | +28.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $345.12M | +95.4% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $176.60M | n/m | 2024-03-21, Balance as of period end |
| 2021-12-31 | -$64.20M | n/c | 2023-03-31, Balance as of period end |
| 2020-12-31 | -$21.86M | n/a | 2022-03-10, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $739.83M | +66.8% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $654.31M | +107.5% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $307.42M | +453.3% |
| MannKind Corp (MNKD) | 2025-12-31 | -$51.02M | n/m |
| uniQure N.V. (QURE) | 2025-12-31 | $198.90M | n/m |
| CorMedix Inc. (CRMD) | 2025-12-31 | $405.31M | +378.8% |
| Belite Bio, Inc (BLTE) | 2025-12-31 | $770.49M | +428.4% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $647.80M | -4.7% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $715.24M | +38.1% |
Compare IRON, OCUL, VREOF, MNKD side by side · Screen every company in Pharmaceutical Preparations ↗